PT - JOURNAL ARTICLE AU - Mulder, Jan AU - Feresiadou, Amalia AU - Fällmar, David AU - Frithiof, Robert AU - Virhammar, Johan AU - Rasmusson, Annica AU - Rostami, Elham AU - Kumlien, Eva AU - Cunningham, Janet L. TI - Autoimmune Encephalitis Presenting with Malignant Catatonia in a 40-Year-Old Male Patient with Covid-19 AID - 10.1101/2020.07.23.20160770 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.23.20160770 4099 - http://medrxiv.org/content/early/2020/08/04/2020.07.23.20160770.short 4100 - http://medrxiv.org/content/early/2020/08/04/2020.07.23.20160770.full AB - Acute malignant catatonia with autonomic instability developed in a previously healthy man with PCR-verified SARS-CoV-2. CT and MRI were normal, EEG showed slowing and cerebrospinal fluid showed a subtle indication of inflammation. There were no signs of pathology in other organs. 18F-FDG-PET conveyed high bilateral uptake in the striatum. While commercial tests were negative, immunohistochemical staining of mouse brain revealed anti-neuronal IgG antibodies against neuronal targets in the hippocampus, thalamus, striatum and cortex. Early treatment with plasmapheresis and corticosteroid reversed disease progression and may have prevented large-scale neurological damage. We are not aware of other types of encephalitis with such distinct pyramidal tract symptoms and raise the possibility that this may be a novel form of autoimmune encephalitis induced by infection with SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has been funded by the Swedish Medical AgencyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ETHICS: This study was approved by the Swedish Ethical Board. The patient has approved the publication of his case and signed an informed consent form. All animal experiments conformed to the European Communities Council Directive (86/609/EEC) and in accordance with Swedish laws and regulations, and all experiments were approved by the local ethical committee (Stockholms Norra Djurforsoksetiska Namnd N183/14).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable upon request.